Recent Finacing
Recent Raise
Propellon Therapeutics is a Toronto-based developer of WDR5-targeted oncology therapeutics, designing and advancing epigenetic modulators targeting WDR5 for treatment of hematological cancers, led by Dr. David O'Neill.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor